Does Rallies summarize ENSC news?

Yes. Rallies summarizes ENSC news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.

Is ENSC research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ENSC. It does not provide personalized investment advice.

ENSC (Ensysce Biosciences, Inc. Common Stock) Stock Analysis - News

Ensysce Biosciences, Inc. Common Stock (ENSC) is a publicly traded Healthcare sector company. As of May 21, 2026, ENSC trades at $0.31 with a market cap of $2.94M and a P/E ratio of -0.08. ENSC moved +3.27% today. Year to date, ENSC is -70.19%; over the trailing twelve months it is -87.19%. Its 52-week range spans $0.23 to $14.67. Rallies surfaces ENSC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What changed in ENSC news today?

Ensysce Achieves 50% PF614-301 Enrollment, Secures IRB Approval and Expands Patents: Ensysce reached 50% of target enrollment in its pivotal PF614-301 Phase 3 trial and secured IRB approval to initiate Part 3 of the PF614-MPAR-102 overdose-protection study after closing a second financing tranche. It published first peer-reviewed data on MPAR® technology and expanded patent coverage for opioid and ADHD programs.

ENSC Key Metrics

Key financial metrics for ENSC
Metric	Value
Price	$0.31
Market Cap	$2.94M
P/E Ratio	-0.08
EPS	$-3.98
Dividend Yield	0.00%
52-Week High	$14.67
52-Week Low	$0.23
Volume	52.66K
Avg Volume	0
Revenue (TTM)	$5.07M
Net Income	$-10.18M
Gross Margin	0.00%

Latest ENSC News

Ensysce Achieves 50% PF614-301 Enrollment, Secures IRB Approval and Expands Patents — May 15, 2026
Ensysce Biosciences Extends MPAR Overdose Protection Patent in Taiwan to 2042 — May 12, 2026
Ensysce Biosciences Closes $2M Convertible Financing with $0.55 Conversion Price — Apr 7, 2026
Ensysce Biosciences Reaches PF614 Phase 3 Enrollment, Breakthrough Designation; Cash at $4.3M — Mar 30, 2026
Ensysce Biosciences Launches Live Q&A Highlighting PF614 Phase 3 Timeline and Commercial Potential — Mar 4, 2026

Recent ENSC Insider Trades

GOWER BOB G bought 90.29K (~$44.09K) on Mar 2, 2023.
GOWER BOB G bought 270.00K (~$128.98K) on Mar 1, 2023.
GOWER BOB G bought 109.30K (~$53.37K) on Feb 28, 2023.

ENSC Analyst Consensus

ENSC analyst coverage data. Average price target: $0.00.

Common questions about ENSC

What changed in ENSC news today?: Ensysce Achieves 50% PF614-301 Enrollment, Secures IRB Approval and Expands Patents: Ensysce reached 50% of target enrollment in its pivotal PF614-301 Phase 3 trial and secured IRB approval to initiate Part 3 of the PF614-MPAR-102 overdose-protection study after closing a second financing tranche. It published first peer-reviewed data on MPAR® technology and expanded patent coverage for opioid and ADHD programs.
Does Rallies summarize ENSC news?: Yes. Rallies summarizes ENSC news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is ENSC research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ENSC. It does not provide personalized investment advice.